Abstract:Background About 90% of mortality associated with cancer is attributable to metastatic disease. Thus, our ability to treat cancer is largely dependent on the capacity to prevent metastasis. Metabolic reprogramming is recognized to support cellular transformation and tumor initiation; however, whether or how metabolism supports metastasis remains an open question. This study seeks to identify metabolic predictors of metastasis, with the rationale that understanding metabolic changes will lead to novel insights into metastasis and perhaps new therapies to treat metastatic disease. Materials and methods A patient-derived xenograft model was used in which metastasis in mice strongly correlates with metastatic history of patient donors. Tumor cells were originally obtained from melanoma patients and passaged exclusively in highly immunocompromised mice [1]. In this study, 17 of such tumor lines were investigated including 6 lines with low metastatic potential, 9 high metastatic potential and 2 intermediate metastatic potential. Tumor cells were implanted subcutaneously into mice, yielding 62 tumors. 3-4 biopsies from each primary tumor were harvested, for a total of 185 samples. A mass spectrometry (MS)-based analytical platform was used to characterize >150 metabolites in each specimen. The relative abundance of metabolites that contribute most to the distinction of highly metastatic from inefficiently metastatic melanomas was examined using statistical tools. Results Unsupervised hierarchical clustering revealed that in every case, a given tumor biopsy was most closely related to all other biopsies descended from the same parental tumor. In addition, as a frequent mutation in melanoma, BRAFmutant tumors were easily distinguished from BRAF-wild type tumors by their metabolomic signatures. More importantly, several metabolic pathways were found altered significantly when metabolomics profiles between melanoma lines with high or low metastatic potentials were compared. Conclusions The MS-based metabolomic analysis of patient-derived melanoma xenografts demonstrates that tumors contain individual metabolomic identities that can be tracked. It may be possible to identify metabolomic features from primary tumors that predict various aspects of tumor biology, including the propensity to metastasize. The altered metabolic pathways in highly metastatic melanomas are potential therapeutic targets.

Label-Free Prediction of Tumor Metastatic Potential Via Ramanome.

Multi-omics with Dynamic Network Biomarker Algorithm Prefigures Organ-Specific Metastasis of Lung Adenocarcinoma

LC-MS Based Cell Metabolic Profiling of Tumor Cells: a New Predictive Method for Research on the Mechanism of Action of Anticancer Candidates

Identifying Metabolomic Features That Predict Metastasis of Melanoma from a Primary Site

Identification of Key mRNAs as Prediction Models for Early Metastasis of Pancreatic Cancer Based on LASSO

Potential of radiomics analysis and machine learning for predicting brain metastasis in newly diagnosed lung cancer patients

Label-free Raman spectroscopy and machine learning enables sensitive evaluation of differential response to immunotherapy

Identification of metastasis-related long non-coding RNAs in lung cancer through a novel tumor mesenchymal score

Identification of novel diagnostic biomarkers associated with liver metastasis in colon adenocarcinoma by machine learning

Discovery and Validation of a Metastasis-Related Prognostic and Diagnostic Biomarker for Melanoma Based on Single Cell and Gene Expression Datasets.

Raman Spectroscopy Combined with Deep Learning for Rapid Detection of Melanoma at the Single Cell Level.

Prediction of Lymph-Node Metastasis in Cancers Using Differentially Expressed mRNA and Non-coding RNA Signatures

Combining Raman Spectroscopy and Machine Learning to Assist Early Diagnosis of Gastric Cancer.

A radiomics and genomics-derived model for predicting metastasis and prognosis in colorectal cancer

Integrative Analysis of Membrane Proteome and MicroRNA Reveals Novel Lung Cancer Metastasis Biomarkers

Multiplex stimulated Raman scattering imaging cytometry reveals cancer metabolic signatures in a spatially, temporally, and spectrally resolved manner

Brain Metastasis Detection by Resonant Raman Optical Biopsy Method

The application of Raman spectroscopy for the diagnosis and monitoring of lung tumors

RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: finding potential biomarkers for breast cancer.

Raman optical identification of renal cell carcinoma via machine learning

Radiomic-Based Prediction of Lesion-Specific Systemic Treatment Response in Metastatic Disease